Changes in circulating tumor DNA (ctDNA) levels as early as weeks after treatment initiation have been correlated with therapeutic response across multiple studies. This webinar will bring together scientific and industry leaders to examine the evolving evidence linking ctDNA dynamics to clinical outcomes and identify opportunities to strengthen the collective evidence base for ctDNA as an exploratory and potential surrogate endpoint.
The Webinar has now concluded.
Key Highlights:
- Insights from recent studies evaluating ctDNA quantitation as an indicator of therapeutic response.
- Practical applications of ctDNA for internal decision-making and dose optimization.
- Collaborative approaches to expand multi-tumor data generation and strengthen the evidence base required for endpoint qualification.
Why Attend?
- Learn more about how response monitoring with ctDNA could help to accelerate evaluation of therapy efficacy and clinical development
- Attendees can participate in a live Q&A session at the end of the presentation or submit questions in advance of the event via the registration form.
Webinar Leaders
Carol Peña, PhD
Executive Director, Translational Oncology, Merck
Fernando Cruz-Guilloty, PhD
Director, Oncology – Precision Medicine & Diagnostics Lead, Johnson & Johnson
Diana Merino Vega, PhD
Senior Director, Cancer Biomarker Development, AstraZeneca
Minetta Liu, MD
Chief Medical Officer, Natera
John Simmons, PhD
Global VP of Biopharma & Oncology Partnerships, Natera
You May Also Be Interested In…
Learn More About Consulting
- We are specialist life sciences market research and consultants, delivering tailored insights across the full drug development and commercialisation lifecycle.
- Combines scientific expertise, expert networks, and proprietary Beacon data to transform complex data into clear, strategic decisions.
- Provides fully customised research, spanning qualitative interviews, quantitative analysis, and desk research, aligned to your specific business objectives.
- Helps biopharma teams reduce risk, identify opportunities, and accelerate decision-making with actionable, decision-ready insights.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
